Obesity & GLP-1 ETFs
THNR — Amplify Weight Loss Drug & Treatment ETF
Amplify · Active (obesity treatment) · since 2024
Broader metabolic health basket including devices, diagnostics and bariatric care.
- Expense ratio
- 0.59%
- AUM
- $50M
- Dividend yield
- 0.6%
- 1Y return
- +10.4%
- 3Y ann.
- —
- 5Y ann.
- —
- 10Y ann.
- —
- All-time ann.
- —
Top holdings
- Eli Lilly12.10%
- Novo Nordisk9.60%
- Intuitive Surgical5.40%
- Dexcom4.90%
- Hims & Hers4.10%
40 total holdings · 48.0% in the top 10